Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

NCT03468153 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT03468153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03468153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 1, 2018
Completion date
January 1, 2020
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma